Vilobelimab is an anti-C5a antibody currently being investigated in the treamtent of ulcerative pyoderma gangrenosum. Dr. Afsaneh Alavi (Mayo Clinic, Rochester, MN, USA) kindly met with touchIMMUNOLOGY to discuss the unmet needs, the rationale for the use of vilobelimab in the treamtent of ulcerative pyoderma gangrenosum and the findings from the phase 2 study.
The abstract ‘Anti-C5a antibody Vilobelimab (IFX-1) treatment in patients with ulcerative pyoderma gangrenosum: Phase 2, open-label dose escalation trial’ was presented at AAD-VMX 2022, 25-29 March.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD. Â
Questions
- What are the unmet needs in the treatment of ulcerative pyoderma gangrenosum? (0:12)
- What is the rationale for the use of vilobelimab in the treatment of patients with ulcerative pyoderma gangrenosum? (1:52)
- What is the mechanism of action of vilobelimab? (3:29)
- What are the aims, design and inclusion criteria of the phase 2, open-label dose escalation trial? (4:17)
- What were the main outcome measures and how well were these achieved? (5:26)
Disclosures: Afsaneh Alavi discloses consulting for Abbvie, BI, InflaRx, Novartix and UCB; serving on advisory boards for Abbvie, BI, InflaRx, Novartix and UCB; and receiving honoraria from Abbvie, BI, InflaRx, Novartix and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the AAD-VMX annual meeting 2022.
